Here’s what you should know:
1. SeaSpine’s U.S. revenues increased 8 percent year over year to $32 million.
2. The company’s U.S. orthobiologics division increased revenues 8 percent to $17 million, with the spinal implant division posting $14.9 million in revenues, a 9 percent year-over-year increase.
3. The recently launched Shoreline and Mariner systems and the company’s expanded NanoMetalene portfolio contributed to the spinal implant division’s growth.
4.The company posted net losses of $9 million for the quarter, up from $7.1 million last year.
5. SeaSpine’s full-year outlook increased to $154 million to $156 million.
More articles on devices:
Healthcare experts discuss investor interest in orthopedics — 5 key points
University of Maryland children’s medical device competition reveals 5 winners
RTI Surgical reports $9.1M net loss in Q1: 5 details
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
